Real-world data of HER2-low metastatic breast cancer: A population based cohort study.

Autor: Holthuis EI; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands. Electronic address: e.holthuis@nki.nl., Vondeling GT; University of Groningen, Groningen, Netherlands., Kuiper JG; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands., Dezentjé V; The Netherlands Cancer Institute, Amsterdam, the Netherlands., Rosenlund M; Daiichi-Sankyo Europe GmbH; and Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden., Overbeek JA; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands., van Deurzen CHM; Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands.
Jazyk: angličtina
Zdroj: Breast (Edinburgh, Scotland) [Breast] 2022 Dec; Vol. 66, pp. 278-284. Date of Electronic Publication: 2022 Nov 10.
DOI: 10.1016/j.breast.2022.11.003
Abstrakt: Background: With the introduction of investigational human epidermal growth factor receptor 2 (HER2) targeting treatments, thorough understanding of breast cancer with different HER2 expression levels is critical. The aim of this study was to compare clinicopathologic characteristics and survival of patients with metastatic breast cancer according to the level of HER2 expression.
Methods: Women with distant metastatic breast cancer during 2008-2016 were selected from PALGA, the Dutch Pathology Registry, and linked to the PHARMO Database Network. Breast cancer samples were categorised as HER2 immunohistochemistry score 0 (IHC0), HER2-low or HER2+.
Results: Among women with hormone receptor (HR) positive metastatic breast cancer (n = 989), 373 (38%) cancers were HER2 IHC0, 472 (48%) were HER2-low and 144 (15%) were HER2+. Among HR negative patients (n = 272), the proportion of HER2 IHC0, HER2-low and HER2+ was 110 (40%), 104 (38%) and 58 (21%) respectively. Within the HR + cohort, patients with HER2 IHC0 or HER2-low cancer were significantly older compared to HER2+ patients. This age difference was not seen in the HR-cohort. The localisation of distant metastases differed significantly between HER2 IHC0 or HER2-low versus HER2+ cases. Survival rates did not differ markedly by subtypes.
Conclusion: Substantial proportion of patients had a HER2-low breast cancer. No clear differences in survival were found when comparing HER2 and HR status. Getting more granular insights in the level of HER2 expression and addressing HER2-low as a separate category could help to assess the impact of emerging treatment strategies. Therefore, more detailed information on HER2 expression should be routinely reported.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: